Adherium Limited reports a strong uptick in Remote Patient Monitoring revenue and device activations, driven by new reimbursement codes and strategic partnerships, aiming for 10,000 RPM patients by year-end.
- 51% increase in RPM revenue from December 2025 to February 2026
- 43% growth in cumulative RPM device shipments in early 2026
- New CPT reimbursement codes lower billing thresholds and improve efficiency
- RPM device activations up 53% in first two months of 2026
- Target of 10,000 RPM patients by end of 2026 reaffirmed
Strong Momentum in Remote Patient Monitoring
Adherium Limited (ASX:ADR), a leader in digital respiratory health, has reported significant commercial progress for its Hailie® Smartinhaler® and cloud-based platform. Since its last update in December 2025, the company has seen a 51% increase in Remote Patient Monitoring (RPM) revenue, rising from A$68,000 to A$103,000 per month by February 2026. This rapid growth underscores the increasing adoption of Adherium’s technology in managing respiratory conditions such as asthma and COPD.
The company’s RPM revenue for January and February 2026 alone has already surpassed the total revenue recorded in the entire second quarter of the 2026 financial year, highlighting accelerating demand and commercial traction.
Device Shipments and Activations Climb Sharply
Supporting this revenue growth is a marked increase in device shipments and activations. Cumulative RPM device shipments rose by 43% in the first two months of 2026, from 2,149 units at the end of 2025 to 3,071 units by late February. Even more impressive is the 53% jump in device activations, which climbed from 1,425 to 2,183 over the same period. This conversion from shipment to active patient use demonstrates the effectiveness of Adherium’s commercial model and its dedicated Care Team infrastructure.
Reimbursement Tailwinds from New CPT Codes
A key catalyst for this growth is the introduction of new CPT reimbursement codes in the United States, effective from 1 January 2026. These codes, 99445 and 99470, reduce the minimum data requirements and enable earlier and more efficient billing for patient monitoring services. For instance, CPT 99445 lowers the billing threshold to just two days of data per month, compared to the previous 16-day requirement. Additionally, CPT 99470 allows billing for shorter consultations, expanding revenue opportunities.
These regulatory changes provide a significant commercial tailwind, enabling Adherium to accelerate patient onboarding and improve billing efficiency, which is critical in scaling its RPM business model.
Expanding Patient Pipeline and Strategic Partnerships
Adherium’s collaboration with partners such as Allergy Partners has broadened its reach, granting access to approximately 48,000 insurance-verified asthma patients with compatible inhaler devices. This expanding pipeline underpins the company’s confidence in scaling its RPM platform and achieving its ambitious target of 10,000 active RPM patients by the end of 2026.
CEO Dawn Bitz highlighted the rapid scaling from zero RPM revenue at the start of 2025 to over A$100,000 monthly revenue within 14 months, attributing success to strong clinician demand and patient benefits from improved respiratory outcomes.
Looking Ahead: Clinical Validation and Market Impact
Adherium is also anticipating the release of clinical and economic data from the Intermountain Health iCARE Study at the American Thoracic Society International Conference in May 2026. This data is expected to validate the Hailie Platform’s impact on medication adherence and health outcomes, further supporting value-based care contracts with US payers and insurers.
As Adherium continues to build its infrastructure and commercial model, the company’s progress signals a promising trajectory in the digital health space, particularly in respiratory disease management.
Bottom Line?
Adherium’s RPM growth, fuelled by new billing codes and partnerships, sets the stage for a transformative 2026.
Questions in the middle?
- How will the new CPT reimbursement codes impact long-term revenue sustainability?
- What are the cost implications of scaling the Adherium Care Team and infrastructure?
- How might upcoming clinical data influence payer adoption and value-based contracts?